Trial Specifics: This trial is designed to evaluate the safety and preliminary anti-cancer activity of a novel, monoclonal antibody in dogs with measurable cancer. The antibody is administered IV by the study staff every 28 days for up to 5 treatments. There is no placebo in this trial. An estimated 30 client-owned dogs with Lymphoma, [...]
